These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33381926)

  • 1. Clinical utility of current biomarkers for prostate cancer detection.
    Kim JH; Hong SK
    Investig Clin Urol; 2021 Jan; 62(1):1-13. PubMed ID: 33381926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary biomarkers for prostate cancer: a review.
    Hessels D; Schalken JA
    Asian J Androl; 2013 May; 15(3):333-9. PubMed ID: 23524531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
    Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
    Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
    Filella X; Foj L
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary markers aiding in the detection and risk stratification of prostate cancer.
    Raja N; Russell CM; George AK
    Transl Androl Urol; 2018 Sep; 7(Suppl 4):S436-S442. PubMed ID: 30363496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical appraisal of biomarkers in prostate cancer.
    Narayan VM
    World J Urol; 2020 Mar; 38(3):547-554. PubMed ID: 30993424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
    Clark JP; Munson KW; Gu JW; Lamparska-Kupsik K; Chan KG; Yoshida JS; Kawachi MH; Crocitto LE; Wilson TG; Feng Z; Smith SS
    Clin Chem; 2008 Dec; 54(12):2007-17. PubMed ID: 18948370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
    Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
    Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH
    Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical use of novel urine and blood based prostate cancer biomarkers: a review.
    Dijkstra S; Mulders PF; Schalken JA
    Clin Biochem; 2014 Jul; 47(10-11):889-96. PubMed ID: 24177197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer.
    Cani AK; Hu K; Liu CJ; Siddiqui J; Zheng Y; Han S; Nallandhighal S; Hovelson DH; Xiao L; Pham T; Eyrich NW; Zheng H; Vince R; Tosoian JJ; Palapattu GS; Morgan TM; Wei JT; Udager AM; Chinnaiyan AM; Tomlins SA; Salami SS
    Eur Urol Oncol; 2022 Aug; 5(4):430-439. PubMed ID: 33812851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current biomarkers for diagnosing of prostate cancer.
    Stephan C; Jung K; Ralla B
    Future Oncol; 2015; 11(20):2743-55. PubMed ID: 26358139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
    Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
    Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.